Allogene's off-the-shelf CD19 CAR-t clears MRD benchmark in Phase II LBCL trial

Allogene Therapeutics (Nasdaq: ALLO) reported interim futility data from its Phase II ALPHA3 trial showing that cemacabtagene ansegedleucel (cema-cel) achieved MRD negativity in 58.3% of patients versus 16.7% in an observation arm in first-line consolidation large B-cell lymphoma (LBCL) — a 41.6 percentage point absolute difference that exceeded the company's pre-specified clinically meaningful benchmark of 25–30 percentage points drawn from published literature.

Trial specifics

The ALPHA3 trial is a randomized, open-label Phase II study enrolling patients with LBCL who remain MRD-positive after completing first-line chemoimmunotherapy. The protocol-defined futility cutoff was triggered when the 24th patient completed a Day 45 MRD assessment, at which point 12 patients had been evaluated in each arm. The primary endpoint — event-free survival — along with key secondary endpoints of progression-free survival and overall survival, remains blinded. The study is powered to detect a 50% reduction in EFS events and is expected to enroll approximately 220 patients across more than 60 sites, with full accrual anticipated by end of 2027.

The interim MRD clearance rate data carry an important caveat: they derive from 12 patients per arm, a sample size too small to draw reliable conclusions about the magnitude or durability of the treatment effect. The company acknowledged this limitation, noting that baseline disease characteristics were numerically more adverse in the cema-cel arm — all 12 patients had stage III–IV disease, half carried double-hit gene alterations, and IPI scores were higher on average than in the observation group. Whether that imbalance attenuated or inflated the observed MRD difference cannot be determined from the available data.

Alongside the MRD rate, ctDNA dynamics at Day 45 showed a median 97.7% decrease from baseline in the cema-cel arm compared with a 26.6% median increase in the observation arm. The divergence in ctDNA trajectories within 45 days of infusion is consistent with rapid CAR T-mediated cytoreduction, though its relationship to longer-term EFS outcomes in this MRD-guided consolidation setting remains to be established.

The safety profile at this interim snapshot was notable for an absence of the toxicities most associated with CAR T therapy. There were no cases of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease across 12 treated patients. Ten of the 12 were managed entirely outpatient following infusion; the two hospitalizations were attributed to events deemed unrelated to cema-cel — atrial fibrillation and non-cardiac chest pain. Low-grade neurologic events, primarily headache, dizziness, and altered sensation, occurred in six patients in the cema-cel arm versus one in the observation arm, though none reached grade 3 or higher.

The absence of CRS and ICANS at this early stage is the data point most likely to draw attention from the field, given that approved autologous CD19 CAR T therapies — axicabtagene ciloleucel (Yescarta, Kite/Gilead) and lisocabtagene maraleucel (Breyanzi, BMS) — carry substantial toxicity burdens in their approved relapsed/refractory settings, with hospitalization rates reported at approximately 70%–90% within 30 days of infusion. Cross-trial comparisons are limited by differences in patient population, disease stage, prior treatment history, and trial design, and the ALPHA3 interim data reflect a first-line consolidation context with lower disease burden than the relapsed/refractory settings where autologous products have been evaluated.

The strategic context

The strategic logic of the ALPHA3 trial rests on a disease biology argument that has gained traction in recent years: MRD status after first-line therapy is a predictor of relapse in LBCL, and intervening in the MRD-positive window — before overt clinical recurrence — could improve long-term outcomes in patients who would otherwise be observed. No therapy is currently approved for this setting. The ALPHA3 comparator arm is observation alone, which means cema-cel, if the primary EFS endpoint is met, would be competing against the current standard of watchful waiting rather than against another active agent.

Cema-cel is an allogeneic, off-the-shelf anti-CD19 CAR T product, meaning it is manufactured from donor T cells rather than the patient's own cells. This eliminates the apheresis and manufacturing wait time associated with autologous CAR T, which typically requires two to four weeks and constrains access to specialized academic centers. Allogene reported that community cancer centers — including sites with little or no prior CAR T experience — accounted for approximately 33% of screening activity and infusions in ALPHA3. That figure, if sustained as the trial scales to its full enrollment target, would represent a meaningful shift in the delivery model for cellular therapy in lymphoma.

The allogeneic CAR T field has faced its own setbacks. Allogene itself paused development of an earlier anti-CD19 allogeneic product following a chromosomal abnormality finding in a patient in 2021, and the broader allogeneic CAR T space has struggled to demonstrate the durable efficacy seen with autologous products in relapsed/refractory disease. Cema-cel's differentiation in ALPHA3 relies partly on the hypothesis that earlier intervention in lower-burden disease — rather than head-to-head competition with autologous products in refractory settings — is where an off-the-shelf product can establish clinical value. Whether MRD clearance at Day 45 in 12 patients translates into a statistically and clinically meaningful EFS benefit in 220 patients remains the central unanswered question.

Allogene anticipates an interim EFS analysis in mid-2027 and the primary EFS readout in mid-2028. A positive primary analysis could support a Biologics License Application submission. Cema-cel was developed under an exclusive license from Cellectis to Servier, with Allogene holding exclusive rights in the US, all EU member states, and the UK.

---

Spot something wrong? Report an issue with this article